Long-Term Use of Aldosterone-Receptor Antagonists in Uncontrolled Hypertension: A Retrospective Analysis
Figure 4
Systolic (SBP) (a), diastolic (DBP) (b) blood pressure and medication use (defined daily dose, DDD) (c) at baseline and end of followup after stratification for followup duration for patients with essential hypertension (Figure 3) and primary aldosteronism (Figure 4). Indicated in (c) is the DDD for the aldosterone-receptor antagonist (ARA). For baseline, this is added up to total DDD; at the end of followup, this is part of the total DDD since ARA was started at baseline. Differences were tested with paired -test for SBP and DBP and Wilcoxon Signed Ranks test for DDD (DDD without ARA at baseline versus DDD including ARA at the end of followup).
